CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors, including the anti-programmed death 1 (PD-1) antibody and the anti-programmed death-ligand 1 (PD-L1) antibody, have been approved for the treatment of advanced-stage NSCLC and have been shown to cure a population of NSCLC patients even at an advanced stage1,2.